A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Celgene
- Study ID
- NCT03930953
- Phase
- PHASE1/PHASE2
- Status
- Active Not Recruiting
Conditions
- Lymphoma, Non-Hodgkin
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- CC-99282 — DRUGSpecified dose on specified days
- Rituximab — DRUGSpecified dose on specified days
- Obinutuzumab — DRUGSpecified dose on specified days
- Tafasitamab — DRUGSpecified dose on specified days
- Valemetostat — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Key Dates
- Start date
- May 20, 2019
- Status verified
- Feb 2026
- Primary completion
- Apr 7, 2027
- Completion
- Feb 9, 2028
Study Design
- Enrollment
- 438 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part A: Dose Escalation
- Experimental: Part B: Dose Expansion
Primary Outcome Measure
Incidence of Adverse Events (AEs) [ Time Frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years) ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 109 | Scottsdale | Arizona | 85259 | - |
| Local Institution - 111 | Jacksonville | Florida | 32224 | - |
| Local Institution - 102 | Tampa | Florida | 32207 | - |
| Local Institution - 108 | Overland Park | Kansas | 66210 | - |
| Local Institution - 107 | Rochester | Minnesota | 55905 | - |
| Local Institution - 104 | St Louis | Missouri | 63110 | - |
| Local Institution - 103 | Hackensack | New Jersey | 07601 | - |
| Local Institution - 101 | Houston | Texas | 77030 | - |
Find similar trials in Scottsdale, AZ
Related Studies
- Family Study of Lymphoproliferative DisordersRecruiting · Mayo Clinic · Rochester, Minnesota
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling By Invitation · Mayo Clinic · Scottsdale, Arizona
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama